Stock Analysis:Pacira Pharmaceuticals (NASDAQ:PCRX) Stock Target Has Just Been Increased
In an analyst note shared with investors and clients by Nomura on 18 December, Pacira Pharmaceuticals (NASDAQ:PCRX) had its price target upgraded to $100.00. The firm presently has a solid “Buy” rating on shares.
From a total of 10 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX) stock, 0 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that NaN of the ratings are positive. The highest target price is $123 while the lowest target price is $52. The mean of all analyst targets is $84.3 with a 7.38% above today’s ($75.99) stock price. Pacira Pharmaceuticals was the topic of 8 analyst reports since July 28, 2015 according to the firm StockzIntelligence Inc. Nomura initiated shares on September 29 with “Buy” rating.
Approximately 1.18M shares of stock traded hands or 54.77% up from the average. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has declined 5.41% since May 15, 2015 and is downtrending. It has underperformed by 1.60% the S&P500.
The overall sentiment of institutions has increased to 1.23 in Q2 2015. Its up 0.29, from 0.94 in 2015Q2. The ratio is positive, as 40 institutions have sold all the shares of Pacira Pharmaceuticals Inc that they owned while 46 funds have taken shares off the table. 34 funds have purchased shares for the first time while 72 added to their positions. These institutions now hold 40.32 million shares or 4.05% less than the 42.02 million shares they owned in 2015Q2.
The Fund Key Colony Management Llc currently is holding shares equating to 19.52% of its total portfolio in Pacira Pharmaceuticals Inc representing a total of 356,942 shares. Another fund,Sarissa Capital Management Lp, is holding a total of 380,000 shares equating to 3.86% of their holdings. Additionally, Biondo Investment Advisors Llc has a 256,209 share stake in Pacira Pharmaceuticals Inc which represents 3.5% of their total portfolio. The Fund, Daruma Capital Management Llc, based out of New York, has also built up a stake in the stock, which represents a total of 2.63% of their total portfolio. Finally Hoplite Capital Management L.P., a fund which is based in the state of New York reported a total holdings of 1.42 million shares.
Insider activity is a very important aspect to track on any stock. Going back to March 16, 2015, shareholders of Pacira Pharmaceuticals Inc have witnessed 1 insider purchase, and a total of 3 selling transactions equating to a net activity of approximately $1.45 million . Stack David M sold 15,000 shares worth approximately $563,561. Scibetta James S bought 5,000 shares worth approximately $306,850. Hastings Paul J sold 3,000 shares worth approximately $180,060. Riker Lauren Bullaro sold 5,000 shares worth approximately $476,700. The company insider Pace Gary W bought 1,000 shares worth $93,830.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $2.69 billion. The Firm is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. It has 280.25 P/E ratio. The Company’s primary focus lies in the development of non-opioid products for postsurgical pain control.
According to Zacks Investment Research, “Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc. is based in New Jersey.”